Abstract
We examined 454,712 exomes for genes associated with a wide spectrum of complex traits and common diseases and observed that rare, penetrant mutations in genes implicated by genome-wide association studies confer ∼10-fold larger effects than common variants in the same genes. Consequently, an individual at the phenotypic extreme and at the greatest risk for severe, early-onset disease is better identified by a few rare penetrant variants than by the collective action of many common variants with weak effects. By combining rare variants across phenotype-associated genes into a unified genetic risk model, we demonstrate superior portability across diverse global populations compared to common variant polygenic risk scores, greatly improving the clinical utility of genetic-based risk prediction.
One sentence summary Rare variant polygenic risk scores identify individuals with outlier phenotypes in common human diseases and complex traits.
Competing Interest Statement
Employees of Illumina, Inc. are indicated in the list of author affiliations. Patents related to this work are (1) Covariate correction including drug use from temporal data, filing No.: 63/351317; (2) Optimized burden test based on nested t-tests that maximize separation between carriers and non-carriers, filing No.: 63/351283; (3) Rare variant polygenic risk scores, filing No.: 63/351299.
Funding Statement
TMB is supported by funding from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation program (grant agreement No. 864203), PID2021-126004NB-100 (MINECO/FEDER, UE), "Unidad de Excelencia Maria de Maeztu", funded by the AEI (CEX2018-000792-M), NIH 1R01HG010898-01A1 and Secretaria d'Universitats i Recerca and CERCA Programme del Departament d'Economia i Coneixement de la Generalitat de Catalunya (GRC 2021 SGR 00177). HR receives funding from Illumina, Inc. to support rare disease gene discovery and diagnosis.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study used genetic and phenotypic data from the UK Biobank (Resource Application Number 33751) and Mass General Brigham Biobank (MGB) (protocol 2018P001236).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Revised Figure 1A to reflect main text. Main text cites number of significant gene-phenotype pairs by using missense variants *with* prioritization by PrimateAI-3D (1,510), but old Figure 1A was showing the number of gene-phenotype associations by using missense variants *without* prioritization (1,033).
Data Availability
PrimateAI-3D prediction scores are available with a noncommercial license upon request and are displayed at https://primad.basespace.illumina.com. Source code is available open source under an academic license upon request
